13.06.2020 18:30:25
|
AstraZeneca Inks Contract With Europe's IVA To Supply 400 Mln Doses Of COVID-19 Vaccine
(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) said on Saturday that it has signed a contract with Europe's Inclusive Vaccines Alliance to supply up to 400 million doses of the University of Oxford's COVID-19 vaccine.
The contract signed by Europe's Inclusive Vaccines Alliance or IVA, a group formed by France, Germany, Italy and the Netherlands.
The company said that the deliveries will start by the end of 2020 and adding that it was seeking to expand manufacturing of the vaccine to meet its commitment to support access to the vaccine at no profit during the pandemic.
AstraZeneca said it continues to build a number of supply chains in parallel across the world, including for Europe.
The company has recently completed similar agreements with the UK, US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million doses.
The company also agreed a licence with the Serum Institute of India for the supply of an additional one billion doses, principally for low- and middle-income countries.
The company stated that the total manufacturing capacity currently stands at two billion doses.
Pascal Soriot, Chief Executive Officer, said: " With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response."
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
06.02.25 |
NASDAQ-Handel: So steht der NASDAQ 100 am Nachmittag (finanzen.at) | |
06.02.25 |
NASDAQ 100 aktuell: NASDAQ 100 liegt am Mittag im Plus (finanzen.at) | |
06.02.25 |
AstraZeneca-Aktie deutlich höher: AstraZeneca schlägt Erwartungen - Gewinn könnte 2025 weiter steigen (finanzen.at) | |
06.02.25 |
Börse New York: NASDAQ 100 verbucht zum Start Gewinne (finanzen.at) | |
03.02.25 |
AstraZeneca-Aktie tiefer: Offenbar kein Impstoff-Werk nahe Liverpool mehr geplant (Dow Jones) | |
28.01.25 |
AstraZeneca feiert Erfolg: Brustkrebsmittel Enhertu erhält FDA-Zulassung - Aktie legt zu (Dow Jones) | |
22.01.25 |
Erste Schätzungen: AstraZeneca legt Quartalsergebnis vor (finanzen.net) | |
15.01.25 |
Börse New York: NASDAQ 100 beginnt Handel mit Gewinnen (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 70,50 | -1,40% |
|